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Abstract  30 
 31 
Amyloid beta peptides (Aβ) proteins play a key role in vascular pathology in Alzheimer’s 32 
Disease (AD) including impairment of the blood brain barrier and aberrant angiogenesis.  33 
Although previous work has demonstrated a pro-angiogenic role of Aβ, the exact mechanisms 34 
by which amyloid precursor protein (APP) processing and endothelial angiogenic signalling 35 
cascades interact in AD remain a largely unsolved problem. Here, we report that increased 36 
endothelial sprouting in human-APP transgenic mouse (TgCRND8) tissue is dependent on β-37 
secretase (BACE1) processing of APP. Higher levels of Aβ processing in TgCRND8 tissue 38 
coincides with decreased NOTCH3/JAG1 signalling, over-production of endothelial filopodia 39 
and increased numbers of vascular pericytes. Using a novel in vitro approach to study sprouting 40 
angiogenesis in TgCRND8 organotypic brain slice cultures (OBSCs), we find that BACE1 41 
inhibition normalises excessive endothelial filopodia formation and restores NOTCH3 42 
signalling. These data present the first evidence for the potential of BACE1 inhibition as an 43 
effective therapeutic target for aberrant angiogenesis in AD. 44 
Key Words:  amyloid precursor protein, NOTCH3, beta secretase-1, angiogenesis 45 
Significance  46 
In this study, we show that targeting amyloid beta processing provides an opportunity to 47 
selectively target tip cell filopodia-driven angiogenesis and develop therapeutic targets for 48 
vascular dysfunction related to aberrant angiogenesis in AD. Our data provide the first evidence 49 
for a safe level of BACE1 inhibition that can normalize excess angiogenesis in AD, without 50 
inducing vascular deficits in healthy tissue. Our findings may pave the way for the development 51 
of new angiogenesis dependent therapeutic strategies in Alzheimer’s Disease. 52 
 53 
Introduction 54 
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Alzheimer’s disease (AD) is closely associated with alterations in the vascular system 55 
1. Multiple studies in humans and animal models have described pathological vascular changes 56 
in AD 2, including disruption to the neurovascular unit 3 and blood-brain barrier 4, increased 57 
microvessel density 3,5,6, arteriolar and venular tortuosity 7,8 and vascular Aβ accumulation 9. 58 
Such changes will likely compromise the effective delivery of oxygen and nutrients to the 59 
brain, so understanding whether vascular alterations are a cause or consequence of aspects of 60 
AD pathology, notably Aβ accumulation, is required in order to design effective therapies. 61 
Amyloid beta peptides, particularly Aβ1-42, are hallmarks of AD 10. These peptides are 62 
the result of sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-63 
secretase enzyme activity. Whilst it is reported that synapse loss is the best correlate of clinical 64 
outcome in AD 11, it is unclear as to whether pathological APP processing products drive this 65 
effect by a direct action on neurons, or indirectly such as through aberrant angiogenesis. 66 
Despite widespread interest in the role of brain vasculature in AD, little is known about how 67 
amyloid-induced vascular changes alter pathological sprouting angiogenesis.  68 
Sprouting angiogenesis is responsible for the formation of new blood vessels in the 69 
cortex. This process (both pathological and physiological) encompasses sequential events 70 
including; sprouting at the vascular front of endothelial cells, extension of sprouts, the 71 
formation of new vascular loops, and pericyte recruitment 12–14. Pericyte recruitment is closely 72 
linked to endothelial cell sprouting. Endothelial tip cells secrete platelet derived growth factor 73 
(PDGF) that activates platelet derived growth factor receptor beta (PDGFRβ) on pericytes to 74 
induce their migration to the sprout 15,16. Endothelial sprouting is regulated by the NOTCH 75 
signaling pathway 17. NOTCH receptors (NOTCH1-4) undergo proteolytic processing via γ-76 
secretase in a manner comparable to that of APP 18,19 resulting in the hypothesis that 77 
interactions between these signaling pathways could underlie the angiogenic pathology in AD 78 
20,21.  79 
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Whilst indirect measures of angiogenic activity, such as vessel density, can be studied 80 
in post mortem brains, active processes, such as filopodia extension from tip cells, are 81 
notoriously difficult to observe in vivo. Mechanistic exploration of pathological angiogenesis 82 
using drugs, such as BACE1, is also complicated by issues of blood-brain barrier penetration 83 
and peripheral effects (such as metabolic changes) that may confound interpretation of results 84 
22. To permit mechanistic exploration of the relationship between amyloid pathology, NOTCH 85 
signaling and pathological angiogenesis, we used organotypic brain slice cultures (OBSCs), 86 
which provide an excellent experimental platform for such studies. OBSCs initially retain a 87 
dense network of capillaries and neurovascular units alongside maintenance of neuronal 88 
architecture and non-neuronal cell populations 23–25. Crucially, OBSCs provide a 3-dimensional 89 
culture system that supports the formation of new blood vessels and are amenable to 90 
pharmacological manipulation, live imaging and repeated measurements without interference 91 
from peripheral systems 26–29. We and others have previously shown that OBSCs are powerful 92 
tools for investigating the progression of AD-like alterations including Aβ accumulation 30, 93 
synaptic disruption 27,31 and cerebrovascular damage 32.  94 
In this study, we find evidence for early pathological angiogenesis in the brains of 95 
postnatal TgCRND8 mice which was recapitulated in OBSCs. In addition to increased vessel 96 
density, OBSCs from TgCRND8 mice showed an increase in sprouting angiogenesis, that 97 
could be completely blocked by BACE1 inhibition. We investigate the mechanisms by which 98 
pathological APP processing and NOTCH signalling interact to induce excessive vascular 99 
sprouting and discuss the implications for the blood vessel pathology seen in AD. 100 
Results  101 
 102 
TgCRND8 mice show vascular abnormalities in the cortex 103 
 104 
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Vascular abnormalities have been widely reported in a range of amyloidosis mouse 105 
models, with conflicting reports demonstrating both increased and decreased  microvessel 106 
density in adult transgenic mice 3,5,33. Here, we sought to examine whether TgCRND8 mice 107 
show evidence of early pathological angiogenesis, as a potential reaction to the initiating steps 108 
of amyloidosis, where therapeutic intervention is more likely to be effective. We studied P7 109 
TgCRND8 mouse post mortem cortex to determine whether a mutant huAPP transgene (and 110 
associated dysregulated amyloid processing), leads to pathological changes in the organisation 111 
of the vascular network and endothelial cell physiology during postnatal development (30,31) 112 
(Fig. 1). PECAM-1 (a marker of endothelial cells) expressing cortical blood vessels of P7 113 
TgCRND8 mice (Fig. 1b, b’) appeared to be more tortuous than cortical vessels of P7 WT 114 
mice (Fig. 1a,a’). When assessing PDGFRβ+ pericyte coverage of blood vessels in P7 115 
TgCRND8 cortex, we found an approximately 2-fold higher pericyte coverage when compared 116 
to WT (Fig. 1c) with coverage becoming almost complete (Fig. 1b). We also found a 117 
significant increase in PECAM-1+ vessel density (Fig. 1d), with no significant alteration in 118 
vessel diameter (Fig. 1e).  119 
 120 
Characterisation of sprouting angiogenesis in organotypic brain slice cultures 121 
 122 
We next sought to establish potential mechanisms by which the presence of a mutant 123 
huAPP transgene results in pathological angiogenesis. For this we required an experimental 124 
system in which key angiogenic processes could be easily observed and manipulated. We 125 
established an ex vivo cortical organotypic brain slice culture (OBSC) system to analyse this 126 
highly regulated process and found we were able to identify multiple stages of sprouting 127 
angiogenesis in OBSCs from wild-type (WT) mice (summarised in Fig. 2e) that were not 128 
observable in post mortem brain (Fig. 1).  PECAM-1 staining showed a dense network of blood 129 
vessels expressing basal membrane protein laminin in 7-days in vitro cortical slices (Fig. 2a). 130 
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Endothelial tip cells were found either along the trunk of PECAM-1+ blood vessels with few 131 
filopodia (Fig. 2b, asterisk) or at the leading edge of vascular sprouts extending numerous 132 
filopodia (Fig. 2b-c) indicating active sprouting angiogenesis. The filopodia of some vascular 133 
sprouts were also found to engage with those of a nearby endothelial tip cells to form a bridge 134 
and the formation of new blood vessels (Fig. 2d).  135 
PDGFRβ+ pericytes were found around the OBSC blood vessels and with long 136 
cytoplasmic processes surrounding the abluminal surface of endothelium (Fig. 3a-c).  High 137 
magnification confocal imaging showed that PDGFRβ expressing pericytes were closely 138 
associated with the PECAM-1+ vascular sprouts (Fig. 3d-e, framed image) and astrocytes 139 
within neurovascular units (Fig. 3f-h) at 7 days in vitro. Taken together, this demonstrates the 140 
utility of OBSCs as a tool to assess different steps of sprouting angiogenesis, including 141 
filopodia formation and pericyte coverage.  142 
Excessive vascular sprouting is associated with increased vascular density and number of 143 
pericytes in TgCRND8 OBSCs 144 
 145 
To determine whether OBSCs recapitulated our in vivo observations, we next looked 146 
for signs of vascular abnormalities in 7 days in vitro TgCRND8 OBSCs (Fig. 4).  The capillary 147 
density (as measured by area of PECAM-1 staining) was significantly higher in TgCRND8 148 
OBSCs compared to cultures from WT littermates (Fig. 4a-b). PECAM-1+ cells were found to 149 
co-localise with Ki67 (a marker of cell division) (Supplementary Fig. 1), potentially 150 
indicating increased endothelial proliferation as a contributor to increased vascular density.   151 
Confocal microscopy also revealed an increase in the number of filopodia found both at the 152 
leading edge, as well as along the body, of the vascular sprouts in TgCRND8 cultures (Fig. 4c) 153 
alongside a 50% increase in the number of filopodia at the vascular sprout of the blood vessels 154 
(Fig. 4d). Interestingly, OBSCs from an alternative amyloidosis mouse model (5xFAD) 155 
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showed similar changes, with a significant increase in PECAM-1+ vessel length and area 156 
(Supplementary Fig. 2a-c) and a substantial increase in filopodia number (Supplementary 157 
Fig. 2d-e) compared to WT littermate controls, indicative of conserved mechanisms between 158 
models. 159 
In 7 days in vitro TgCRND8 OBSCs, the number of PDGFRβ+ pericytes around the 160 
capillaries was significantly higher than WT controls (Fig. 5a-b) even when normalised to the 161 
increased density of blood vessels (Fig. 5c). The increased number of PDGFRβ+ pericytes was 162 
correlated with an upregulation of PDGFRβ protein expression as measured by western blot 163 
(Fig. 5d-e).  164 
Inhibition of BACE1 activity normalises vascular density and hypersprouting in 165 
TgCRND8 OBSCs 166 
 167 
To investigate if higher vascular density and filopodia number depend on the increased 168 
production of Aβ seen in TgCRND8 OBSCs, we applied the BACE1 inhibitor LY2886721 to 169 
OBSCs for 7 days in vitro (Fig. 6a). This inhibitor has been extensively characterised both in 170 
vivo and in vitro and found to be a potent and highly selective BACE inhibitor (with essentially 171 
no inhibition of cathepsin D, pepsin, renin or other similar aspartyl proteases) 34. Using ELISA, 172 
we found that BACE1 inhibitor completely abolished the generation of Aβ1-40 and Aβ1-42 in the 173 
TgCRND8 OBSC culture medium (Fig. 6b) in agreement with previous characterisation of this 174 
inhibitor 34. Interestingly, Aβ was found to colocalise with blood vessels in TgCRND8 OBSCs, 175 
but was absent in WT vessels (Supplementary Fig. 3 a-b). Vascular Aβ was completely 176 
abolished by BACE1 inhibitor treatment (Supplementary Fig. 3b). BACE1 inhibition reduced 177 
the vascular density in TgCRND8 slices back to WT levels, with no additional effect on WT 178 
cultures (Fig. 6c-e).  Quantification of PECAM-1+ capillaries revealed a two-fold increase in 179 
total vessel length in TgCRND8 OBSCs, which was restored to WT levels after BACE1 180 
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inhibition (Fig. 6f). Similarly, BACE1 inhibition reduced the excessive sprouting activity of 181 
PECAM-1+ endothelial cells in TgCRND8 OBSCs, significantly lowering the number of 182 
filopodia at the leading edge of the vascular sprout back to WT levels (Fig. 6g-i). Conversely, 183 
direct application of synthetic huAβ1-42 to WT cultures resulted in a significant increase in 184 
PECAM-1+ vessel density and length (Supplementary Fig. 4a-d), further supporting a 185 
hypothesis whereby the overproduction of Aβ in TgCRND8 tissue can trigger pathological 186 
angiogenesis.  187 
Despite significant rescue of hypersprouting (Fig. 6) we found that BACE1 inhibition 188 
did not normalise the increased levels of PDGFRβ in TgCRND8 OBSCs (Supplementary Fig. 189 
5). Indeed, BACE1 inhibition increases the levels of PDGFRβ in WT OBSCs, but this is 190 
uncoupled from the lack of change seen in PECAM-1+ vessel coverage, length and filopodia 191 
number (Fig. 6).  192 
BACE1 inhibition restores Notch3 and Jag1 mRNA levels in TgCRND8 cortical slices 193 
 194 
Given that modulating APP/Aβ metabolism via BACE1 inhibition resulted in 195 
normalisation of hypersprouting, we hypothesised that interaction between Aβ peptide 196 
processing and NOTCH signalling might explain the endothelial hypersprouting observed in 197 
TgCRND8 mice. To test this hypothesis, we examined the mRNA levels of key components 198 
of the NOTCH signalling pathway, NOTCH1, NOTCH3, JAG1, JAG2 and DLL4, in control 199 
versus BACE-inhibitor treated TgCRND8 and WT littermate OBSCs. Real time quantitative 200 
PCR analysis showed that mRNA levels of Notch3 (Fig. 7a) and Jag1 (Fig. 7b) were 201 
significantly lower in TgCRND8 OBSCs when compared to the WT controls, whilst expression 202 
of Notch1, Jag2 and DLL4 were not significantly changed (Fig. 7c-e). 5μM BACEI inhibitor 203 
treatment for 7 days in vitro normalised both Notch3 and Jag1 mRNA expression back to the 204 
levels observed in WT cultures (Fig. 7a-b). We found no significant changes in the mRNA 205 
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expression of Notch1, Jag2, DLL4 in TgCRND8 or WT slices after BACE1 inhibitor treatment 206 
(Fig. 7c-e).  Interestingly, application of synthetic Aβ to WT slices for 3 days in vitro resulted 207 
in a reduction in Notch3 mRNA (Supplementary Fig. 4e) but did not alter the levels of Jag1 208 
mRNA (Supplementary Fig. 4f), potentially indicating that changes to Notch3 are upstream 209 
to alterations in Jag1. 210 
BACE1 inhibition induces cleavage of NOTCH3 intracellular domain (NICD3) in 211 
TgCRND8 cortical slices 212 
 213 
Finally, we analysed how higher production of Aβ affects NOTCH3 and NOTCH1 214 
signalling activity in TgCRND8 OBSCs (Fig. 7f-i). Translocation of the NOTCH intracellular 215 
domain (NICD) into the nucleus is a negative regulator of endothelial sprouting 17, so we tested 216 
whether the reduction in Notch3 mRNA led to lower levels of NICD3.  Western blot analysis 217 
showed a trend for reduced levels of NOTCH3 intracellular domain (NICD3) in TgCRND8 218 
cortical slices (Fig 7f-g). In contrast, BACE1 inhibitor treatment significantly increased NICD3 219 
levels in TgCRND8 slices to at least the level of WT cortical cultures (Fig. 7f-g). Consistent 220 
with the mRNA levels of Notch1, there was no effect of genotype or BACE1 inhibition on the 221 
appearance of NOTCH1 intracellular domain (NICD1) (Fig. 7h-i).  222 
 223 
Discussion 224 
 225 
In this study, we explored the relationship between Aβ processing, NOTCH signalling 226 
and pathological angiogenesis in cortical tissue from huAPP transgenic mice. We report that 227 
BACE1 inhibition can reverse the increased pathological angiogenesis observed in TgCRND8 228 
OBSCs alongside restoration of NOTCH signalling. We find that pathological angiogenesis is 229 
an early event in TgCRND8 mice, and is detectable before amyloid plaque formation, synapse 230 
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loss or cognitive deficits 35. Restoration of physiological levels of angiogenesis early in the 231 
disease course may therefore be an important target for AD therapeutics.  232 
This study took advantage of the OBSC system to explore mechanisms of pathological 233 
angiogenesis that are difficult to study in vivo. OBSCs are a potent, underused tool for 234 
exploring vascular phenotypes 23,36,37 with few prior studies seeking to explore this in 235 
combination with AD models 32,38. Interestingly, the increased sprouting angiogenesis we 236 
observed in TgCRND8 OBSCs is more pronounced than we find in vivo at a similar age. The 237 
OBSC method likely stresses the tissue via the slicing injury and/or the isolation from the 238 
systemic vasculature; stimulating sprouting angiogenesis. By allowing visualisation of such 239 
processes in both WT and TgCRND8 tissue, the OBSC system appears to unmask a mechanism 240 
that underlies the vascular changes in AD models that may otherwise be overlooked. 241 
Our finding that tissue from postnatal TgCRND8 mice shows pathological angiogenesis 242 
is of interest in the context of aging being a major risk factor for AD. Studies examining human 243 
brain microvessel density in the context of “normal” ageing have revealed inconsistent results 244 
(increased/ decreased/ no change) in aged versus young individuals depending on brain region 245 
and microvessel type studied 39–42. Despite widespread interest in vascular pathology in AD, 246 
there is also debate as to the relative roles of pro- and anti- angiogenic processes during disease 247 
progression 1. For example, whilst some studies demonstrate increased angiogenesis in post 248 
mortem human AD or huAPP-mouse brain 3,5,6,43, others report endothelial cell apoptosis and 249 
loss of vasculature 33,44. It seems likely that such studies represent different stages of disease, 250 
with initial increases in angiogenesis (potentially as a result of rising Aβ that occurs in ageing 251 
45,46) being overtaken by cell death in the end stages 1. Clearly, more work is required to fully 252 
understand the complex relationships between age, AD and vascular pathology, although our 253 
work indicates pathological angiogenesis can be induced by dysregulated Aβ processing even 254 
in the absence of ageing.  255 
11 
 
A potential role for Aβ as a regulator of angiogenesis has been previously proposed 256 
from observations in both physiological and pathological conditions. In post mortem human 257 
AD brains, it has been shown that increased vascular density in the hippocampus 6 and pericyte-258 
mediated capillary restriction 47 correlates with Aβ load. In amyloid mouse models, 259 
immunisation with Aβ peptides cleared plaques and restored capillary density to normal levels 260 
48 whilst inhibition of Aβ aggregation reduced arteriolar Aβ accumulation and tortuosity 7.  261 
Application of synthetic Aβ to a number of models has also highlighted its pro-angiogenic role 262 
with increased endothelial cell proliferation, capillary bed density and vascular sprouting seen 263 
both in vitro and in vivo 20,49,50. Our use of a novel OBSC platform that endogenously expresses 264 
mutant APP with all its processing products allows for careful exploration of the effects of Aβ 265 
as well as other APP-derived products on vascular pathology 51–53. Our findings add weight to 266 
growing evidence that dysregulation of amyloid processing, or exogenously applied huAβ1-42 267 
(Supplementary Fig. 4), can stimulate pathological angiogenesis. It is worth noting, that 268 
whilst we were unable to analyse the exact form (monomeric, oligomeric etc.) of Aβ present 269 
in the TgCRND8 cultures (due to the presence of serum in the culture medium and very low 270 
concentration in the slice tissue itself) we know from our previous work that the Aβ present, 271 
and thus likely responsible for our observed phenotypes, is soluble, thioflavin-S negative and 272 
is not sequestered in extracellular plaques 27.  273 
A key finding in this study is that over-production of Aβ in TgCRND8 OBSCs is 274 
accompanied by reduced expression of the angiogenesis suppressor NOTCH3 and its ligand 275 
JAG1, providing a novel mechanistic insight into how amyloid pathology potentially impacts 276 
angiogenesis in AD. Previous studies have shown that Notch3 knockout increases retinal 277 
vascular density and endothelial tip formation 54 and silencing NOTCH3 in tumours promotes 278 
pathological angiogenesis 55. NOTCH ligand JAG1 has also been implicated in angiogenic 279 
processes, with Jag1 targeting antisense oligonucleotides potentiating FGF-responsive tube 280 
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formation and invasion in vitro 56. There are multiple potential mechanisms by which Notch3 281 
and Jag1 could be downregulated in postnatal TgCRND8 tissue, which we summarise in our 282 
working hypothesis (Fig. 8).  283 
NOTCH proteins and NOTCH ligands are substrates for the γ-secretase presenilin 57, 284 
resulting in the production of NICD which translocates to the nucleus to regulate gene 285 
expression (Fig. 8a). Cleavage of NOTCH3 by γ-secretase has been found to induce Notch3 286 
and Jag1 transcription via autoregulatory mechanisms 58. Previous work has also shown that 287 
NOTCH3 activation (by cleavage to NICD3) is prevented by treatment with γ-secretase 288 
inhibitors 59 which results in increased angiogenic sprouting 60. Interestingly, this effect is 289 
mimicked by the application of synthetic monomeric Aβ potentially pointing to an enzymatic 290 
feedback inhibition, whereby high levels of Aβ lower the activity of γ-secretase 49. This study 291 
aligns with our findings that application of synthetic Aβ to WT OBSCs results in increased 292 
microvessel density alongside a reduction in Notch3 mRNA (Supplementary Fig. 4). In 293 
TgCRND8 tissue (Fig. 8b) increased levels of Aβ may act via this mechanism to inhibit the 294 
efficacy of γ-secretase, reducing levels of NOTCH3 cleavage and so lowering Notch3 and Jag1 295 
transcription, ultimately resulting in increased sprouting angiogenesis. Alternatively, other 296 
APP processing products may also have inhibitory effects on γ-secretase. β-CTF, the result of 297 
BACE1 cleavage of APP, contains a region (Aβ17–23) that has been found to modulate γ-298 
secretase activity by non-competitive inhibition 61 and a similar role has been proposed for the 299 
APP intracellular domain (AID) 19. Alternatively, increased expression of APP, or enhanced 300 
processing of APP through γ-secretase may directly compete with NOTCH ligands for 301 
enzymatic availability 62.  302 
In this study, we find that excessive endothelial filopodia formation and reduced 303 
NOTCH3/JAG1 signalling in TgCRND8 OBSCs can be normalized via application of BACE1 304 
inhibitor (Fig. 8b) indicating a likely role for BACE1-dependent APP processing products. 305 
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Interestingly, PDGFRβ protein remained elevated in BACE1-inhibitor treated TgCRND8 306 
cultures and such treatment increased PDGFRβ in WT cultures (Supplementary Fig. 5), 307 
without impacting vascular phenotypes (Fig. 6). The role of pericytes in angiogenesis is 308 
dynamic and at times opposing 63, with contrasting studies demonstrating their presence 309 
promotes early angiogenesis and vessel survival 13,64–66, whilst inhibiting endothelial cell 310 
proliferation or inducing vessel regression in later stages 67–69. This raises the possibility that 311 
increased pericyte expression could be a compensatory attempt at terminating pathological 312 
angiogenesis in TgCRND8 cultures which only becomes effective after normalisation of Aβ 313 
levels. BACE1 treatment in WT cultures may end ongoing physiological angiogenesis, 314 
resulting in the proliferation of pericytes on the stabilised, mature vessels. Alternatively, 315 
BACE1 may have an independent role in regulating PDGFRβ signalling that is uncoupled, at 316 
least in the short-term, from alterations in endothelial filopodia or microvessel density. BACE1 317 
inhibitors have previously been shown to inhibit angiogenesis and tumour growth 70. BACE1 318 
knockout mice show reduced vascular density 71 and treatment of zebrafish with BACE1 319 
inhibitors was found to induce similar deficits, with application of Aβ restoring normal 320 
vascularisation 72. Whilst we hypothesise that the normalisation of TgCRND8 angiogenesis 321 
after BACE1 inhibition is due to reduced levels of Aβ, we have to consider the possibility that 322 
BACE inhibition has a direct effect on angiogenic processes unrelated to APP. Other studies 323 
have found that BACE1 directly regulates JAG1 shedding, with BACE1-/- mice showing an 324 
increase in Jag1 levels and downstream NOTCH signalling 73. This seems an unlikely 325 
mechanism in our system, however, due to the observation that BACE1 inhibition has no effect 326 
on the levels of Jag1 (Fig. 7b) or vascular density (Fig. 6) in WT OBSCs and that application 327 
of synthetic Aβ alone increases PECAM-1+ vessel density (Supplementary Fig. 4). From our 328 
results, however, it is possible that BACE1 plays an independent role in pericyte recruitment/ 329 
PDGFRβ expression, which warrants further exploration.  Future studies could also examine 330 
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whether the rescue effect of BACE1 inhibition on pathological angiogenesis is reversible, 331 
providing greater insight into the dynamics of angiogenesis in response to changes in amyloid 332 
processing. 333 
Further mechanistic studies are needed to better understand the interplay between 334 
NOTCH signalling and APP processing mechanisms in AD. Here, we propose that APP 335 
overexpression or feedback inhibition from high Aβ/ β-CTF concentration in TgCRND8 336 
OBSCs reduces γ-secretase-dependent cleavage of NOTCH3 (Fig. 8). Our results also indicate 337 
that there may be a safe level of BACE1 inhibition that can restore physiological levels of 338 
angiogenesis, without inducing angiogenic deficits in healthy tissue. 339 
 340 
Methods 341 
 342 
Mice 343 
TgCRND8 mice 35 were maintained on a mixed BL6:sv129 background. TgCRND8 mice 344 
overexpress human APP with both the Swedish (K670N/M671L) and Indiana (V717F) 345 
mutations. 5xFAD mice 74 were maintained on a C57BL/6 x SJL background. 5xFAD mice 346 
express human APP with the Swedish (K670N/M671L), Florida (I716V) and London (V717I) 347 
mutations, alongside human PSEN1 with the M146L and L286V mutations. TgCRND8 or 348 
5xFAD heterozygote males were bred with wild-type background matched females to produce 349 
both wild-type and transgenic heterozygote littermates. Animals were kept on a 12hr:12hr 350 
light:dark cycle at a constant temperature of 19ᵒC in a pathogen-free environment. All animal 351 
work was approved by the Babraham Institute Animal Welfare and Ethical Review Body, the 352 
University of Cambridge and the UK Home Office, and carried out in accordance with the 353 
Animals (Scientific Procedures) Act, 1986. 354 
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Organotypic brain slice cultures 355 
Cortical organotypic brain slice cultures were made from humanely sacrificed P6-P9 356 
littermates of either sex according to the method of de Simoni et al and our previous work 357 
27,31,75. Briefly, after schedule 1, brains were kept on ice in dissection buffer (EBSS 358 
supplemented with 25mM HEPES and 1 x Penicillin/Streptomycin). 350μm thick sagittal 359 
sections of cortex were cut using a Leica VT1000S vibratome and slices collected using a 360 
modified sterile 3ml Pasteur pipette. On average 6 cortical slices were collected per pup and 361 
stored in dissection buffer on ice until plating. For long term culture, slices were transferred, 362 
in a class II hood, onto sterile Millicell® membrane inserts (Millipore PICM0RG50) in 35mm 363 
culture dishes (Nunc). 3 cortical slices from the same pup were plated to a single membrane, 364 
with two dishes made per animal. Inserts were maintained in 1ml of maintenance medium 365 
according to the following recipe: 50% MEM with Glutamax-1 (Life Technologies 42360-366 
024), 25% Heat-inactivated horse serum (Life Technologies: 26050-070), 23% EBSS (Life 367 
Technologies: 24010-043), 0.65% D-Glucose (Sigma:G8270), 2% Penicillin/Streptomycin 368 
(Life Technologies 15140-122) and 6 units/ml Nystatin (Sigma N1638). Membrane inserts 369 
were handled with sterile forceps and the medium was changed 100% 4 hours after plating and 370 
at 4 div. OBSCs were maintained at 37ᵒC, 5% CO2 and high humidity for 7 div.  For BACE1 371 
inhibition experiments, 1 culture per pup was treated with 5µM BACE1 inhibitor LY2886721 372 
(Selleckchem S2156) (previously reported to have high potency and specificity both in vivo 373 
and in vitro 34)  and compared with a DMSO treated control from the same animal. Cultures 374 
were treated for the entire 7 days in vitro.  375 
Immunohistochemistry  376 
OBSCs 377 
OBSCs were fixed for 20 minutes in 4% PFA in phosphate buffered saline (PBS), washed 3 378 
times in PBS, then blocked for 1 hour in PBS supplemented with 0.5% Triton X-100 and 3% 379 
normal Goat Serum (Sigma G9023). Slices were incubated at 4ᵒC in primary antibody (diluted 380 
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in blocking solution) overnight. In order to detect PDGFR, heat-mediated antigen retrieval 381 
was performed in 10 mM citrate buffer (pH 6.0) for 40 min at 80°C prior to primary antibody 382 
incubation. Slices were washed a further 3 times in 0.5% Triton-X100 in PBS (PBS-TX) then 383 
incubated with secondary antibodies (Life Technologies and Jackson) (1:500 dilution in 384 
blocking solution for 2 hours at 4ᵒC). Three final PBS-TX washes were conducted before slices 385 
were mounted on slides and images captured using a Leica Confocal Microscope. Primary 386 
antibodies used: rabbit anti-PDGFR (28E1) (1:200, Cell Signalling, Cat. No: 3169S), rat anti-387 
PECAM-1 (1:400, BD, Cat. No: 550274), rabbit anti-laminin (1:200, Sigma, Cat. No: L9393), 388 
Mouse MOAB-2 (pan Aβ) (1:1000, Merck-Millipore, Cat. No: MABN254) Rabbit Ki67 389 
(1:1000, Abcam, Cat. No: ab15580) secondary staining was conducted using species-specific 390 
fluorophore-conjugated (Streptavidin Alexa 488, Molecular Probes; Cy3 or Cy5, Jackson,) or 391 
biotin-conjugated secondary antibodies (Jackson). DAPI (1μg/mL, Sigma) was used to 392 
counterstain nuclei.  393 
Cryosections of Postnatal Mouse Brain 394 
P7 WT and TgCRND8 pups, of either sex were culled via cervical dislocation followed by 395 
decapitation. Brains were removed, snap-frozen, and embedded in Tissue-Tek® OCT 396 
compound (Sakura Finetek, The Netherlands). Cryosections were cut at 20μm thickness and 397 
fixed in either ice cold acetone or 2% PFA for 20min and air-dried. Cryosections were then 398 
stained for PECAM-1 and PDGFRβ as described above. 399 
Microscopy and Image Analysis  400 
Images were captured via an epifluorescence microscopy system (Leica DM6000B) or using 401 
confocal microscopes (Leica, Zeiss LSM780). Figures were composed using Photoshop CS5 402 
software. All analysis was done blind to genotype and/or treatment condition. 403 
Quantification of pericyte number and coverage 404 
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To quantify the number of PDGFRβ-positive pericytes, cells were counted using NIH Image J 405 
Cell Counter tool. A maximum projection of fifteen-micrometre z-stacks was acquired from 406 
cortex slices freshly derived from WT and TgCRND8. Three pictures were taken at 40X for 407 
each slice. The areas of PDGFR+ pericytes and PECAM-1+ blood vessels were separately 408 
subjected to threshold processing and the respective signals for each image was calculated 409 
using NIH Image J Area Measurement tool. Pericyte coverage was determined as a percentage 410 
(%) of PDGFRβ+ pericyte area covering PECAM-1+ capillary surface area per field (ROI) 411 
733x733 m. Three slices per animal were analysed.  412 
Capillary density, length and filopodia quantification 413 
For PECAM-1+ capillary area, sections were analysed with Leica confocal microscope. Three 414 
pictures were taken at 20X for each section. ROI size of 733x733 m for confocal images were 415 
utilized. The area covered by PECAM-1+ capillaries was analysed using the NIH ImageJ area 416 
measurement tool where pictures were subjected to threshold processing to produce a binary 417 
image. The area of PECAM-1 coverage was expressed as percentage of the total area, 3 slices 418 
per WT and TgCRND8 pups (n= 4-5 for each genotype) were analysed. The filopodia of 419 
vascular sprouts were analysed using z-stacked PECAM-1+ blood vessels.  420 
Protein extraction and Western Blot 421 
OBSCs were scraped off the membrane insert using a scalpel and transferred to 2 x Laemelli 422 
buffer supplemented with 10% 2-mercaptethanol (50µL per 3 slices). Samples were boiled for 423 
10 minutes then frozen at -20ᵒC until use. Ten micrograms of protein were separated on a 10% 424 
SDS polyacrylamide gel then transferred onto PVDF membranes. Membranes underwent 425 
blocking (20 mM Tris, 136 mM NaCl, pH 7.6, 0.1% Tween 20, 5% nonfat dry milk) before 426 
incubation with primary antibody anti-NOTCH1/NICD1 (1:750, Abcam, Cat No: ab3294), 427 
NOTCH3/NICD3 (1:1000, Abcam, Cat No: ab23426), PDGFR (28E1), (1:1000, Cell 428 
Signaling, Cat No: 3169S), overnight at 4°C. overnight at 4 °C. Signals were obtained by 429 
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binding of a secondary anti-rabbit horse radish peroxidase (HRP) linked antibody (1:15000, 430 
Sigma-Aldrich, Cat No: A0545) and visualized by exposing the membrane to a charge-coupled 431 
device camera (LAS1000, Fujifilm, Tokyo, Japan) using a chemiluminescence kit (Merck 432 
Millipore, Billerica, MA, USA). Membranes were stripped and reprobed for β-actin (diluted 433 
1:50 000, Sigma-Aldrich, Cat No: A3854). After densitometric analysis using Image J 434 
software, protein levels were calculated as percentage of β-actin expression. 435 
Aβ ELISA 436 
Culture medium from 7 div OBSCs was assayed for human Aβ1-40 and Aβ1-42 using 437 
commercially available ELISA kits (Life Technologies: KHB3441 and KHB3481). Briefly, 438 
medium was incubated with Aβ detection antibody for 3 hours, washed, and then incubated 439 
with an HRP-conjugated antibody for 30 minutes. After another wash step, stabilised 440 
chromogen was added for 30 minutes before the adding an acid-based stop solution. 441 
Absorbance was read at 450nm using a PheraStar ELISA plate reader with the standard curve 442 
calculated  using a 4-parameter fit. Concentration of Aβ in the medium is expressed as pg/ml. 443 
Levels of Aβ were compared between BACE1 treated and DMSO treated TgCRND8 cultures. 444 
Quantification of gene expression by qPCR 445 
Slice cultures were scraped off the membrane and RNA extracted using an RNeasy mini kit 446 
(Qiagen). Briefly, 3 slices were homogenised in 350µL lysis buffer RLT supplemented with 447 
1% 2-mercaptethanol. 350μL 70% ethanol (in nuclease free water) was then added and samples 448 
transferred to RNeasy RNA collection columns. After several wash steps described in the kit 449 
protocol, the RNA was eluted in 20µL nuclease free water, measured and quality tested using 450 
a Nanodrop® and frozen at -80ᵒC until use. cDNA synthesis was performed using 451 
Script™cDNA Synthesis Kit (Bio-Rad). cDNA was analysed using real-time PCR 452 
SsoAdvanced™ SYBR® Green Supermix from Bio-Rad and run on a Bio-Rad CFX96 real-453 
time quantitative PCR (qPCR) system. Gene expression was normalized to the housekeeping 454 
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gene GAPDH. Melt curve analyses were performed to ensure the specificity of qPCR product. 455 
Primer sequences are given in Supplementary Table 1. Values are presented as mean ± SD of 456 
three independent experiments, and within each experiment, triplicate samples were assessed. 457 
Statistical Analysis 458 
Experimental sample sizes were selected via power analysis of preliminary data using an online 459 
calculator: http://powerandsamplesize.com. All samples from the same animal, under the same 460 
treatment conditions were averaged to produce a single biological replicate. Each experiment 461 
was performed on 2-3 independent occasions.  Statistical analysis was conducted using Graph 462 
Pad Prism. Data are expressed as mean ± SD. Two group comparison was performed by using 463 
Student’s t-test (two-sided) and multiple group comparison by one-way or two-way ANOVA 464 
followed by Tukey post hoc test (to correct for multiple comparisons). For Western blot, after 465 
normalisation to the actin signal, the expression of each protein was compared using a two-466 
way ANOVA, followed by Tukey post hoc test. Significance was set at p<0.05.  467 
 468 
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 655 
Figure 1. Vascular morphology in the cortex of postnatal TgCRND8 mice  656 
(a-b) Blood vessels were stained by PECAM-1 and pericytes by PDGFRβ. Increased pericyte 657 
coverage and microvessel tortuosity (arrows and framed areas) is seen in P7 TgCRND8 cortex; 658 
scale bar 20μm. (a´-b´) Enlarged white-framed areas in a and b showing samples of normal 659 
microvessels in WT (a´) and tortuous microvessels (*) in TgCRND8 (b´) cortex; scale bar 660 
10μm. (c) There is increased PDGFRβ+ pericyte coverage in TgCRND8 cortex (*p<0.05). (d) 661 
There is an increase in PECAM-1+ area in TgCRND8 cortex (*p<0.05). (e) No difference in 662 
vessel diameter was detected (p>0.05); mean ± SD (n=2 (WT), n=4 (TgCRND8), Student’s t-663 
test.    664 
 665 
 666 
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 667 
Figure 2.  Characterisation of sprouting angiogenesis in 7-days in vitro organotypic 668 
cortical slice cultures from wildtype mice.  669 
(a) Confocal images of cortical slices stained for PECAM-1 (green) and laminin (red) to 670 
visualize blood vessels at 7 days in vitro, scale bar 500μm. (b-d) Different stages of vascular 671 
sprouting can be visualised in cortical brain slices including; tip cell formation (*) endothelial 672 
tip extension (framed area in (b) which is expanded in (c)) new sprouting (arrow heads) and 673 
bridging (arrow) (scale bar 50 μm) (d).  (e) Diagram summarising the different stages of 674 
sprouting angiogenesis that can be observed in cortical organotypic slice cultures. 675 
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 676 
Figure 3. Pericytes are well preserved in organotypic cortical slices at 7 days in vitro 677 
(a-c) Confocal images showing PECAM-1+ blood vessels (green) (a,c) covered by PDGFR+ 678 
pericytes (red, arrows (a,b)) in 7 days in vitro WT cortical slices; scale bar 20μm. (d) Higher 679 
magnification images of the framed area in (a) with DAPI counterstain depicting nuclei (grey). 680 
Pericytes (arrows) can be seen on the PECAM-1+ angiogenic blood vessels; scale bar 10μm. 681 
(e) depicts enlarged area framed in (d) showing clear vascular sprouting. (f-h) Confocal z-682 
stacks show a preserved cytoarchitecture, consisting of PECAM-1+ blood vessels (green), 683 
surrounded by PDGFR+ pericytes (red) and GFAP+ astrocytes (blue) (DAPI=grey). Arrow 684 
marks the close association between the pericytes and astrocytes; scale bar 20μm. 685 
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 686 
Figure 4.  TgCRND8 organotypic cortical slices show increased vascular density and 687 
excessive filopodia formation when compared to wildtype cultures 688 
(a) Representative confocal images showing blood vessel density (PECAM-1, green) in 7 days 689 
in vitro WT and TgCRND8 slices; scale bar 100μm. (b) Quantification of PECAM-1+ area (as 690 
% of the total image) reveals a significantly higher blood vessel density in TgCRND8 cortical 691 
slices versus WT slices. (mean ± SD (n=5 (WT), n=4 (TgCRND8), *P<0.05 Student’s t-test.) 692 
(c) Confocal images showing endothelial cells extending numerous finger-like filopodia at the 693 
forefront of vascular sprouts in 7 days in vitro WT and TgCRND8 cortical slices, visualized 694 
by PECAM-1 labelling. Red dots highlight vascular sprouting tips, scale bar 20μm. (d) 695 
Quantification shows that the number of filopodia per cell is significantly higher in TgCRND8 696 
when compared to WT slices. (mean ± SD, (n=14 (WT), n=13 (TgCRND8),  *P<0.05 Student’s 697 
t-test) 698 
 699 
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 700 
Figure 5. Increased pericyte number and PDGFR expression in TgCRND8 organotypic 701 
cortical slices 702 
(a) Representative confocal images showing PDGFR+ pericytes (arrows) around blood 703 
vessels (PECAM-1, green) in 7 days in vitro WT and TgCRND8 slices; scale bar 50μm. 704 
PDGFR+ pericytes are closely associated with cortical microvessels. (a´) The framed areas in 705 
(a) are enlarged, scale bar 50μm. (b) Quantification of PDGFR+ pericytes reveals an increased 706 
number in 7 days in vitro TgCRND8 slices when compared to WT (data are expressed as cell 707 
numbers per mm3. (c) Quantification of PDGFR+ staining area normalised to PECAM-1+ 708 
staining area shows a significant increase in pericyte coverage in TgCRND8 OBSCs; mean ± 709 
SD. (n=4 (WT), n=5 (TgCRND8), *P<0.05 Student’s t-test). Representative Western blots (d) 710 
and quantification of PDGFR band intensity (e) in 7 days in vitro WT and TgCRND8 cortical 711 
slices, shows increased PDGFR in TgCRND8 cultures when normalised to Actin control (n=5  712 
(WT), n=4  (TgCRND8) **P<0.01 Student’s t-test). 713 
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 714 
Figure 6.  BACE1 inhibition decreases vascular density and normalises aberrant vascular 715 
sprouting in TgCRND8 organotypic cortical slices 716 
(a) Diagram showing the experimental schedule for BACE1 inhibitor treatment of WT and 717 
TgCRND8 cortical slices. (b) Measurement of Aβ1-40 and Aβ1-42  in the culture medium of 7 718 
day in vitro TgCRND8 slices treated with BACE1 inhibitor (mean ± SEM (n=4), two way 719 
ANOVA effect of treatment ****P<0.0001). (c) Confocal images showing blood vessel 720 
density (PECAM-1, green) in 7 days in vitro control (c) and BACE1 inhibitor (c’) treated WT 721 
slices. (d-d´) Confocal images showing blood vessel density (PECAM-1, green) in 7 days in 722 
vitro control (d) and BACE1 inhibitor (d’) treated TgCRND8 slices; scale bar 20μm.  BACE1 723 
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inhibition rescues the increase in PECAM1+ area (% image coverage) (mean ± SD (n=4 (WT), 724 
n=4 (TgCRND8), *P0.05, two-way ANOVA) (e) and total vessel length (mm/mm2) (mean ± 725 
SD (n=4 (WT), n=4 (TgCRDN8), **P0.01 and *P<0.05, two-way ANOVA) (f) seen in 726 
control treated TgCRND8 cultures. PECAM-1 staining of WT (g-g’) and TgCRND8 (h-h’) 727 
slice cultures with (g’,h’) or without (g,h) BACE1 inhibitor treatment. Individual filopodia are 728 
highlighted with red dots. (i) Quantification of the number of filopodia per cell demonstrates 729 
that BACE1 inhibitor rescues the increased number seen in untreated TgCRND8 cultures when 730 
compared to WT at 7 days in vitro (mean ± SD, (n=4 (WT), n=4 (TgCRND8), ****P0.0001, 731 
two-way ANOVA).  732 
 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
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 745 
Figure 7. NOTCH signalling in BACE1-treated organotypic cortical slices. 746 
 (a-e) Quantitative gene expression analysis of NOTCH receptors (Notch1 and -3) and NOTCH 747 
ligands (Dll4, Jag1, Jag2) in 7 days in vitro WT and TgCRND8 OBSCs treated with BACE1 748 
inhibitor. Untreated TgCRND8 OBSCs show a significant reduction in the levels of Notch3 (a) 749 
and Jag1 (b) compared to WT cultures. BACE1 inhibitor treatment normalised the expression 750 
levels of Notch3 (a) and Jag1 (b) in TgCRND8 cortical slices (mean ± SD, n=5 (WT), n=6 751 
(TgCRDN8),  *P0.05 and **P0.01, two-way ANOVA). BACE1 inhibitor treatment had no 752 
35 
 
effect on the expression of Notch1 (c), Jag2 (d), and DLL4 (e) in 7 days in vitro TgCRND8 or 753 
WT cortical slices, (mean ± SD, n=5 (WT), n=6 (TgCRND8), P>0.05, two-way ANOVA). (f-754 
g) Representative Western blots and quantification of NOTCH3 intracellular domain (NICD3) 755 
in 7 days in vitro WT and TgCRND8 cortical slices treated with BACE1 inhibitor. (Data 756 
expressed in band intensity; mean ± SD, *P0.05, n=4 (WT), n=12 (TgCRND8), two-way 757 
ANOVA, Tukey post hoc test.) (h-i) Representative Western blots and quantification of Notch1 758 
intracellular domain (NICD1) in 7 days in vitro WT and TgCRND8 cortical slices treated with 759 
BACE1 inhibitor (Data expressed in band intensity; mean ± SD, n=9 (WT), n=14 (TgCRND8), 760 
P>0.05, two-way ANOVA). 761 
 762 
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 765 
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 767 
 768 
 769 
 770 
 771 
 772 
 773 
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 774 
Figure 8. Proposed mechanism for the enhancement of sprouting angiogenesis by 775 
BACE1-dependent APP processing 776 
Schematic diagram of our working hypothesis for increased sprouting angiogenesis in 777 
TgCRND8 (b) compared to WT (a) tissue. Increased APP processing by BACE1 in TgCRND8 778 
OBSCs competes with NOTCH3 for γ -secretase or reduces γ-secretase activity, thereby 779 
lowering transcriptional signalling through NICD. This reduces Notch3-Jag1 expression via 780 
autoregulatory mechanisms, thereby releasing the inhibitory influence on sprouting 781 
angiogenesis. Created with BioRender. 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
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Supplementary Methods 790 
Treatment of OBSCs with synthetic Aβ  791 
Synthetic Aβ was prepared according to previously published protocols for the production of 792 
monomeric Aβ 76. Briefly, 1mg of synthetic human Aβ1-42 (California Peptide Research, Inc) 793 
was dissolved in 222μl 1,1,1,3,3,3,-Hexafluro-2-Propanol (HFIP) and reconstituted for 30 794 
minutes. 10μl aliquots were loaded into low-bind tubes and HFIP evaporated via running 795 
samples in a SpeedVac at room temperature for 10 minutes. The dried peptide films were stored 796 
at -20°C over desiccant until use. For monomeric Aβ, the peptide film was dissolved in 5μl 797 
DMSO to a final concentration of 2mM huAβ1-42 and left to reconstitute for 15 minutes before 798 
sonicating in a bath sonicator for 10 minutes. huAβ1-42 or DMSO-only control was then 799 
immediately added to freshly prepared wild-type OBSCs at a final concentration of 1μM for 3 800 
days in vitro before slices were harvested for RNA analysis or fixed for quantification of 801 
PECAM-1+ blood vessels.  802 
 803 
 804 
Supplementary Figures 805 
 806 
 807 
 808 
 809 
 810 
 811 
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 812 
Supplementary Figure 1. PECAM-1+ blood vessels co-express Ki67 in WT and TgCRND8 813 
organotypic cortical slices 814 
Representative 3D confocal images showing PECAM-1+ endothelial cells that are positive for 815 
Ki67 (a proliferation marker) in 7 days in vitro WT (upper) and TgCRND8 (lower) OBSCs. 816 
Scale bar 20μm. 817 
 818 
 819 
 820 
 821 
 822 
 823 
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 824 
Supplementary Figure 2. Increased vascular density and excessive filopodia formation in 825 
5xFAD organotypic cortical slices  826 
(a) Representative confocal images showing blood vessel density (PECAM-1, green) in 7 days 827 
in vitro WT and 5xFAD slices; scale bar 50μm. (b-c) Quantification of PECAM-1+ vessel 828 
length (b) (mean ± SD (n=5 (WT), n=4 (5xFAD), *P<0.05 Student’s t-test)  and PECAM-1+ 829 
vessel area (as % of the total image)  (c)  (mean ± SD (n=5 (WT), n=4 (5xFAD), ***P<0.001 830 
Student’s t-test) reveals a significantly higher blood vessel density in 5xFAD cortical slices 831 
versus WT slices. (d) Confocal images showing PECAM-1+ endothelial cells extending 832 
numerous finger-like filopodia at the forefront of vascular sprouts in 7 days in vitro WT and 833 
5xFAD cortical slices, scale bar 20μm. (e) Quantification shows that the number of filopodia 834 
per cell is significantly higher in 5xFAD when compared to WT slices. (mean ± SD, (n=11 835 
(WT), n=17 (5xFAD),  ****P<0.0001 Student’s t-test). 836 
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 837 
Supplementary Figure 3.  BACE1 inhibitor decreases Aβ expression around PECAM-1+ 838 
blood vessels in TgCRND8 organotypic cortical slices 839 
(a) Representative confocal images showing that there is no expression of Aβ in PECAM-1+ 840 
blood vessels in 7 days in vitro control (upper panel) and BACE1 inhibitor (lower panel) 841 
treated WT slices; scale bar 20μm. (b) Representative confocal images showing high 842 
expression of Aβ in PECAM-1+ blood vessels in control treated TgCRND8 slices (upper 843 
panel), whereas BACE1 inhibition decreases Aβ expression in treated TgCRND8 (lower 844 
panel); scale bar 20μm 845 
 846 
 847 
 848 
 849 
 850 
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 851 
Supplementary Figure 4. Synthetic Aβ1-42 treatment increases vascular density and 852 
decreases NOTCH3 mRNA levels in WT organotypic cortical slices 853 
(a) Diagram showing the experimental schedule for Aβ treatment of WT cortical slices. (b) 854 
Confocal images showing blood vessel density (PECAM-1) in 3 days in vitro control (left) and 855 
huAβ1-42 (right) treated WT slices, scale bar 20μm. Aβ1-42 treatment increases total vessel 856 
length (mm/mm2) (mean ± SD (n=4 (Ctrl), n=4 (Aβ treated), **P0.01, Student’s t-test)  (c) 857 
and PECAM-1+ area (% image coverage) (mean ± SD (n=4 (Ctrl), n=4 (Aβ treated), *P<0.05, 858 
Student’s t-test) (d) when compared to control slices. (e-f) Quantitative gene expression 859 
analysis of a NOTCH receptor (Notch3) and NOTCH ligand (Jag1) in 3 days in vitro WT 860 
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cortical slices treated with Aβ1-42. Aβ1-42 treatment decreases the expression levels of Notch3 861 
mRNA in WT cortical slices (mean ± SD (n=5 (Ctrl), n=5 (Aβ treated), *P0.05, Student’s t-862 
test)  (e) but  has no effect on the expression of Jag1 mRNA (mean ± SD (n=5 (Ctrl), n=5 (Aβ 863 
treated), P>0.05, Student’s t-test)  (f). 864 
 865 
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 877 
 878 
 879 
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 881 
Supplementary Figure 5. BACE1 inhibitor has no effect on PDGFR levels in TgCRND8 882 
organotypic cortical slices. 883 
(a) Representative Western blots and quantification of PDGFR in 7 days in vitro WT and 884 
TgCRND8 cortical slices treated with BACE1 inhibitor. (b) BACE1 inhibitor increases 885 
PDGFR protein levels in 7 days in vitro WT cortical slices, however BACE1 inhibitor 886 
treatment had no effect on the expression of PDGFR in TgCRND8 slices. (Data expressed in 887 
band intensity; mean ± SD, **P0.01, *P0.05, n=6 (WT), n=6 (TgCRND8), two-way 888 
ANOVA, Tukey post hoc test.). 889 
 890 
 891 
 892 
 893 
 894 
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 895 
Supplementary Table 1. Primer Sequences for qPCR experiments 896 
 897 
